Abstract
Aging is associated with dysfunction in the cholinergic system, including degeneration of basal forebrain cholinergic terminals that innervate the cortex, which directly contributes to age- and disease-related cognitive decline. In this study, we used [18F]fluoroethoxybenzovesamicol ([18F]FEOBV) positron emission tomography (PET) imaging to assess the effect of age on cholinergic terminal integrity in predefined regions of interest and its relationship to cognitive performance in healthy older adults who underwent neuropsychological assessment and FEOBV PET brain imaging. Our results showed age-related reductions in FEOBV binding, particularly in the anterior cingulate cortex-our primary region of interest-as well as in the striatum, posterior cingulate cortex, and primary auditory cortex. Notably, FEOBV binding in the anterior cingulate cortex was positively correlated with cognitive performance on the NIH EXAMINER Executive Composite Score. These findings suggest that [18F]FEOBV PET imaging can be used as a reliable biomarker to assess cholinergic changes in the human brain and indicate that preserving the cholinergic integrity of the basal forebrain may help maintain cognitive function and protect against age-related cognitive decline.
Competing Interest Statement
Conflicts of Interest and Financial Disclosures: MA, TVV, and SJG are employees at Posit Science, the company that develops BrainHQs brain training and assessment programs. They are shareholders of Posit Science stock. EDS, ADFP, PJT and LO declare no competing interests.
Clinical Trial
NCT04149457
Clinical Protocols
https://www.researchprotocols.org/2024/1/e59705
Funding Statement
Funding Sources: Research reported in this publication was supported by the National Institute on Aging of the National Institutes of Health under Award Numbers R44AG039965 and 3R44AG039965-06S1 awarded to MA and TVV. The funders had no role in design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication. This content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study protocol was developed in accordance with the Declaration of Helsinki guidelines and was approved by WIRB (IRB00000533) and REB of McGill University Health Centre (2020-6474). The radioligand FEOBV was approved by Health Canada (Control # 252085).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
Data available: Yes Data types: Deidentified participant data (imaging, cognitive, behavioral) When available: Two years after trial completion (on May 31, 2026), the INHANCE dataset will be made available to verified academic and industry researchers. Investigators can conduct both confirmatory and exploratory analyses using LORIS, a freely accessible, open-source data archive with provenance-sharing features. Access the dataset here: https://inhance.loris.ca/